Pulmonary Surfactant: Emerging Protein Analogues.
- Published in:
- BioDrugs, 1999, v. 11, n. 2, p. 71, doi. 10.2165/00063030-199911020-00001
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 1999 AND VI 11 AND IP 2
Results: 9
1
2
Current Status of Gene Therapy for Rheumatoid Arthritis.
- Published in:
- BioDrugs, 1999, v. 11, n. 2, p. 103, doi. 10.2165/00063030-199911020-00004
- By:
- Publication type:
- Article
3
Liposomal Influenza Vaccine.
- Published in:
- BioDrugs, 1999, v. 11, n. 2, p. 137, doi. 10.2165/00063030-199911020-00007
- By:
- Publication type:
- Article
4
Liposomal Influenza Vaccine: A Viewpoint by John S. Oxford.
- Published in:
- BioDrugs, 1999, v. 11, n. 2, p. 145, doi. 10.2165/00063030-199911020-00008
- By:
- Publication type:
- Article
5
Clinical Experience with Growth Hormone Treatment in Patients with β-Thalassaemia Major.
- Published in:
- BioDrugs, 1999, v. 11, n. 2, p. 79, doi. 10.2165/00063030-199911020-00002
- By:
- Publication type:
- Article
6
Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-α and Antineoplastic Drugs.
- Published in:
- BioDrugs, 1999, v. 11, n. 2, p. 87, doi. 10.2165/00063030-199911020-00003
- By:
- Publication type:
- Article
7
Liposomal Influenza Vaccine: A Viewpoint by Janet E. McElhaney.
- Published in:
- BioDrugs, 1999, v. 11, n. 2, p. 145, doi. 10.2165/00063030-199911020-00009
- By:
- Publication type:
- Article
8
Pharmacokinetics of the Recombinant Thrombolytic Agents: What is the Clinical Significance of Their Different Pharmacokinetic Parameters?
- Published in:
- BioDrugs, 1999, v. 11, n. 2, p. 115, doi. 10.2165/00063030-199911020-00005
- By:
- Publication type:
- Article
9
Interferon-τ: Prospects for Clinical Use in Autoimmune Disorders.
- Published in:
- BioDrugs, 1999, v. 11, n. 2, p. 125
- By:
- Publication type:
- Article